2022
Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis
Kayali S, Pasta A, Torres M, Jaffe A, Strazzabosco M, Marenco S, Giannini EG. Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis. Liver International 2022, 43: 8-17. PMID: 36102312, PMCID: PMC10087158, DOI: 10.1111/liv.15419.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsLiver transplant recipientsGraft rejectionOverall survivalICI therapyCheckpoint inhibitorsICI treatmentPooled analysisSystematic reviewDe novo malignanciesAcute graft rejectionDisease control rateRecurrent hepatocellular carcinomaShorter overall survivalGraft lossNovo malignanciesLiver transplantationLT recipientsTransplant recipientsAdvanced malignanciesProspective studyControl rateCase reportHepatocellular carcinomaPatients
1998
Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery
Iemmolo R, Rossanese A, Rotilio A, Mattisi G, Gerunda G, Merenda R, Neri D, Crepaldi G, Strazzabosco M. Cerebral aspergillosis in a liver transplant recipient: a case report of long-term survival after combined treatment with liposomal amphotericin B and surgery. Journal Of Hepatology 1998, 28: 518-522. PMID: 9551693, DOI: 10.1016/s0168-8278(98)80329-2.Peer-Reviewed Original ResearchConceptsLiver transplant recipientsLiposomal amphotericin BTransplant recipientsCerebral aspergillosisAmphotericin BLife-threatening complicationsLiposomal amphotericin B.Complication-free survivalRisk of recurrenceSystemic side effectsAspergillus fumigatus infectionLong-term survivalSurgical excisionCase reportFumigatus infectionLimited efficacyCerebrospinal fluidSide effectsMortality rateAmphotericin B.AspergillosisRecipientsSurvivalTreatmentFirst report